Adial Pharmaceuticals(ADIL) - 2025 Q2 - Quarterly Results

FORM 8-K Filing Information This section provides an overview of the Form 8-K filing, including registrant details and report specifics Registrant Information This section provides essential identification details for Adial Pharmaceuticals, Inc., including its legal and operational information, and its status as an emerging growth company - Adial Pharmaceuticals, Inc. is a Delaware corporation[2][3] Registrant Details | Detail | Value | | :--- | :--- | | Exact Name of Registrant | Adial Pharmaceuticals, Inc. | | State of Incorporation | Delaware | | Trading Symbol | ADIL | | Exchange Registered | The Nasdaq Stock Market LLC (Nasdaq Capital Market) | | Emerging Growth Company | Yes | Filing Details This section specifies the date of the report and confirms the filing is a Current Report on Form 8-K, indicating it is not intended to satisfy other specific filing obligations - The report date is August 14, 2025, for the earliest event reported on the same date[2] - The filing is a Current Report on Form 8-K, not simultaneously satisfying other specified filing obligations under Rule 425, Rule 14a-12(b), Rule 14d-2(b), or Rule 13e-4(c)[2][3] Item 2.02 Results of Operations and Financial Condition This section reports the company's financial performance for the quarter, including the announcement and legal disclaimers Announcement of Financial Results Adial Pharmaceuticals, Inc. announced its financial results for the fiscal quarter ended June 30, 2025, through a press release furnished as an exhibit to this 8-K report - On August 14, 2025, Adial Pharmaceuticals, Inc. issued a press release containing financial information for the fiscal quarter ended June 30, 2025[5] - A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K[5] Legal Disclaimer The company clarifies that the financial information provided in this Item 2.02 and the accompanying press release is furnished, not filed, and is therefore not subject to certain liabilities or incorporated by reference into other SEC filings - The information in Item 2.02 and Exhibit 99.1 is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934[6] - The information is not subject to the liabilities of Section 18 or Sections 11 and 12(a)(2) of the Securities Act of 1933[6] - The information shall not be incorporated by reference into any other SEC filing made by the Company[6] Item 9.01 Financial Statements and Exhibits This section details the financial statements and other documents included as exhibits to the Form 8-K filing List of Exhibits This section lists the documents furnished as exhibits to the Form 8-K, primarily the press release detailing the financial results and the interactive data file Exhibit List | Exhibit Number | Exhibit Description | | :--- | :--- | | 99.1 | Press Release, issued by Adial Pharmaceuticals, Inc. on August 14, 2025 | | 104 | Cover Page Interactive Data File (XBRL) | SIGNATURES This section provides the formal authorization and signatory details for the filed report Authorization and Signatory This section formally concludes the report with the required signatures, confirming the registrant's authorization and the identity of the signing officer - The report was duly signed on behalf of ADIAL PHARMACEUTICALS, INC. pursuant to the requirements of the Securities Exchange Act of 1934[10] Signatory Details | Detail | Value | | :--- | :--- | | Date | August 14, 2025 | | Signatory Name | Cary J. Claiborne | | Signatory Title | President and Chief Executive Officer |